CLBX
NEUTRALCelLBxHealth Announces Additional Subscription
The medical diagnostics company announces an additional subscription, raising further gross proceeds of approximately £0.4 million.
CelLBxHealth
1.2000GBX
9.09%
Market Cap
13.67M
Volume
6.28M
225% of avg
P/E Ratio
-40.94
EPS (TTM)
-0.03
Beta
0.14
Day Range
1.0770p - 1.2000p
52 Week Range
1.0000p1.2000p17.4450p
1.2000p
Upcoming Events
CLBX
NEUTRALCelLBxHealth Completes £7.8m Fundraising
The medical diagnostics company has completed a £7.8m fundraising, including a £0.96m retail offer.
CLBX
NEUTRALCelLBxHealth Announces Fundraising Shares Admission
The healthcare diagnostics company announces an update on the admission of fundraising shares, but details on the raise price and discount are unclear.
CLBX
BADCelLBxHealth Launches Retail Offer at Significant Discount
The healthcare diagnostics company is launching a Retail Offer to raise up to £1 million at a significant 38% discount to the previous closing price, a concerning sign for investors.
CLBX
BADCelLBxHealth Raises £6.8M in Discounted Placing
The medical diagnostics company has raised £6.8 million through a discounted equity placing, indicating potential financial or operational challenges.
CLBX
BADCelLBxHealth Announces £6.8 Million Fundraise at Significant Discount
The healthcare diagnostics company has announced a £6.8 million fundraise at a 38% discount to the previous share price, raising concerns about investor confidence and the company's financial position.
CLBX
GOODCelLBxHealth Announces Collaboration with QIAGEN to Advance CTC-based Research
The medical diagnostics company has entered a collaboration agreement with QIAGEN to promote the Parsortix platform and integrate it with QIAGEN's molecular analysis tools for pharmaceutical partners.
CLBX
NEUTRALCelLBxHealth Presents Proof-of-Concept Study
The medical diagnostics company presents a proof-of-concept study using its Parsortix platform with Roche's automated staining system for cancer biomarker analysis.
CLBX
NEUTRALCelLBxHealth Provides Update on Funding and Expert Consensus on CTCs
The medical diagnostics company provides an update on its funding plans and welcomes an expert consensus on the clinical relevance of its circulating tumor cell technology.
You're all caught up!